MiR-142-3p Prevents Macrophage Differentiation during Cancer-Induced Myelopoiesis

Nada Sonda, Francesca Simonato, Elisa Peranzoni, Bianca Calì, Stefania Bortoluzzi, Andrea Bisognin, Ena Wang, Francesco M. Marincola, Luigi Naldini, Bernhard Gentner, Christian Trautwein, Sara Dutton Sackett, Paola Zanovello, Barbara Molon, Vincenzo Bronte

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Tumor progression is accompanied by an altered myelopoiesis causing the accumulation of immunosuppressive cells. Here, we showed that miR-142-3p downregulation promoted macrophage differentiation and determined the acquisition of theirimmunosuppressive function in tumor. Tumor-released cytokines signaling through gp130, the common subunit of the interleukin-6 cytokine receptor family, induced the LAP*x2217; isoform of C/EBPβ transcription factor, promoting macrophage generation. miR-142-3p downregulated gp130 by canonical binding to its messenger RNA (mRNA) 3' UTR and repressed C/EBPβ LAP* by noncanonical binding toits 5' mRNA coding sequence. Enforced miR expression impaired macrophage differentiation both invitro and invivo. Mice constitutively expressing miR-142-3p in the bone marrow showed a marked increase in survival following immunotherapy with tumor-specific T lymphocytes. By modulatinga specific miR in bone marrow precursors, we thus demonstrated the feasibility of altering tumor-induced macrophage differentiation as a potent tool to improve the efficacy of cancer immunotherapy.

Original languageEnglish
Pages (from-to)1236-1249
Number of pages14
JournalImmunity
Volume38
Issue number6
DOIs
Publication statusPublished - 27 Jun 2013
Externally publishedYes

Fingerprint

Myelopoiesis
Macrophages
Neoplasms
Immunotherapy
Down-Regulation
Bone Marrow
Interleukin-6 Receptors
Messenger RNA
Cytokine Receptors
3' Untranslated Regions
Immunosuppressive Agents
Protein Isoforms
Transcription Factors
Cytokines
T-Lymphocytes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Sonda, N., Simonato, F., Peranzoni, E., Calì, B., Bortoluzzi, S., Bisognin, A., ... Bronte, V. (2013). MiR-142-3p Prevents Macrophage Differentiation during Cancer-Induced Myelopoiesis. Immunity, 38(6), 1236-1249. https://doi.org/10.1016/j.immuni.2013.06.004

MiR-142-3p Prevents Macrophage Differentiation during Cancer-Induced Myelopoiesis. / Sonda, Nada; Simonato, Francesca; Peranzoni, Elisa; Calì, Bianca; Bortoluzzi, Stefania; Bisognin, Andrea; Wang, Ena; Marincola, Francesco M.; Naldini, Luigi; Gentner, Bernhard; Trautwein, Christian; Sackett, Sara Dutton; Zanovello, Paola; Molon, Barbara; Bronte, Vincenzo.

In: Immunity, Vol. 38, No. 6, 27.06.2013, p. 1236-1249.

Research output: Contribution to journalArticle

Sonda, N, Simonato, F, Peranzoni, E, Calì, B, Bortoluzzi, S, Bisognin, A, Wang, E, Marincola, FM, Naldini, L, Gentner, B, Trautwein, C, Sackett, SD, Zanovello, P, Molon, B & Bronte, V 2013, 'MiR-142-3p Prevents Macrophage Differentiation during Cancer-Induced Myelopoiesis', Immunity, vol. 38, no. 6, pp. 1236-1249. https://doi.org/10.1016/j.immuni.2013.06.004
Sonda N, Simonato F, Peranzoni E, Calì B, Bortoluzzi S, Bisognin A et al. MiR-142-3p Prevents Macrophage Differentiation during Cancer-Induced Myelopoiesis. Immunity. 2013 Jun 27;38(6):1236-1249. https://doi.org/10.1016/j.immuni.2013.06.004
Sonda, Nada ; Simonato, Francesca ; Peranzoni, Elisa ; Calì, Bianca ; Bortoluzzi, Stefania ; Bisognin, Andrea ; Wang, Ena ; Marincola, Francesco M. ; Naldini, Luigi ; Gentner, Bernhard ; Trautwein, Christian ; Sackett, Sara Dutton ; Zanovello, Paola ; Molon, Barbara ; Bronte, Vincenzo. / MiR-142-3p Prevents Macrophage Differentiation during Cancer-Induced Myelopoiesis. In: Immunity. 2013 ; Vol. 38, No. 6. pp. 1236-1249.
@article{407ba8e130bd4f6dbf1418edf06425f1,
title = "MiR-142-3p Prevents Macrophage Differentiation during Cancer-Induced Myelopoiesis",
abstract = "Tumor progression is accompanied by an altered myelopoiesis causing the accumulation of immunosuppressive cells. Here, we showed that miR-142-3p downregulation promoted macrophage differentiation and determined the acquisition of theirimmunosuppressive function in tumor. Tumor-released cytokines signaling through gp130, the common subunit of the interleukin-6 cytokine receptor family, induced the LAP*x2217; isoform of C/EBPβ transcription factor, promoting macrophage generation. miR-142-3p downregulated gp130 by canonical binding to its messenger RNA (mRNA) 3' UTR and repressed C/EBPβ LAP* by noncanonical binding toits 5' mRNA coding sequence. Enforced miR expression impaired macrophage differentiation both invitro and invivo. Mice constitutively expressing miR-142-3p in the bone marrow showed a marked increase in survival following immunotherapy with tumor-specific T lymphocytes. By modulatinga specific miR in bone marrow precursors, we thus demonstrated the feasibility of altering tumor-induced macrophage differentiation as a potent tool to improve the efficacy of cancer immunotherapy.",
author = "Nada Sonda and Francesca Simonato and Elisa Peranzoni and Bianca Cal{\`i} and Stefania Bortoluzzi and Andrea Bisognin and Ena Wang and Marincola, {Francesco M.} and Luigi Naldini and Bernhard Gentner and Christian Trautwein and Sackett, {Sara Dutton} and Paola Zanovello and Barbara Molon and Vincenzo Bronte",
year = "2013",
month = "6",
day = "27",
doi = "10.1016/j.immuni.2013.06.004",
language = "English",
volume = "38",
pages = "1236--1249",
journal = "Immunity",
issn = "1074-7613",
publisher = "Cell Press",
number = "6",

}

TY - JOUR

T1 - MiR-142-3p Prevents Macrophage Differentiation during Cancer-Induced Myelopoiesis

AU - Sonda, Nada

AU - Simonato, Francesca

AU - Peranzoni, Elisa

AU - Calì, Bianca

AU - Bortoluzzi, Stefania

AU - Bisognin, Andrea

AU - Wang, Ena

AU - Marincola, Francesco M.

AU - Naldini, Luigi

AU - Gentner, Bernhard

AU - Trautwein, Christian

AU - Sackett, Sara Dutton

AU - Zanovello, Paola

AU - Molon, Barbara

AU - Bronte, Vincenzo

PY - 2013/6/27

Y1 - 2013/6/27

N2 - Tumor progression is accompanied by an altered myelopoiesis causing the accumulation of immunosuppressive cells. Here, we showed that miR-142-3p downregulation promoted macrophage differentiation and determined the acquisition of theirimmunosuppressive function in tumor. Tumor-released cytokines signaling through gp130, the common subunit of the interleukin-6 cytokine receptor family, induced the LAP*x2217; isoform of C/EBPβ transcription factor, promoting macrophage generation. miR-142-3p downregulated gp130 by canonical binding to its messenger RNA (mRNA) 3' UTR and repressed C/EBPβ LAP* by noncanonical binding toits 5' mRNA coding sequence. Enforced miR expression impaired macrophage differentiation both invitro and invivo. Mice constitutively expressing miR-142-3p in the bone marrow showed a marked increase in survival following immunotherapy with tumor-specific T lymphocytes. By modulatinga specific miR in bone marrow precursors, we thus demonstrated the feasibility of altering tumor-induced macrophage differentiation as a potent tool to improve the efficacy of cancer immunotherapy.

AB - Tumor progression is accompanied by an altered myelopoiesis causing the accumulation of immunosuppressive cells. Here, we showed that miR-142-3p downregulation promoted macrophage differentiation and determined the acquisition of theirimmunosuppressive function in tumor. Tumor-released cytokines signaling through gp130, the common subunit of the interleukin-6 cytokine receptor family, induced the LAP*x2217; isoform of C/EBPβ transcription factor, promoting macrophage generation. miR-142-3p downregulated gp130 by canonical binding to its messenger RNA (mRNA) 3' UTR and repressed C/EBPβ LAP* by noncanonical binding toits 5' mRNA coding sequence. Enforced miR expression impaired macrophage differentiation both invitro and invivo. Mice constitutively expressing miR-142-3p in the bone marrow showed a marked increase in survival following immunotherapy with tumor-specific T lymphocytes. By modulatinga specific miR in bone marrow precursors, we thus demonstrated the feasibility of altering tumor-induced macrophage differentiation as a potent tool to improve the efficacy of cancer immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84879569764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879569764&partnerID=8YFLogxK

U2 - 10.1016/j.immuni.2013.06.004

DO - 10.1016/j.immuni.2013.06.004

M3 - Article

VL - 38

SP - 1236

EP - 1249

JO - Immunity

JF - Immunity

SN - 1074-7613

IS - 6

ER -